GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited, headquartered in India and operating within the "Other business services (74)" industry, has disclosed its carbon emissions for recent years.

For the reporting year 2024, the company reported total Scope 1 and Scope 2 emissions of approximately 10.7 million kg CO2e. This figure includes approximately 774,320 kg CO2e from Scope 1 emissions and approximately 9.96 million kg CO2e from Scope 2 emissions.

In the preceding year, 2023, GlaxoSmithKline Pharmaceuticals Limited's combined Scope 1 and Scope 2 emissions amounted to approximately 10.69 million kg CO2e, comprising about 486,950 kg CO2e for Scope 1 and approximately 10.2 million kg CO2e for Scope 2.

For the reporting year 2023, the company's Scope 1 and Scope 2 emissions totalled approximately 10.99 million kg CO2e. This consisted of about 286,210 kg CO2e from Scope 1 and approximately 10.71 million kg CO2e from Scope 2.

It is important to note that the available emissions data for GlaxoSmithKline Pharmaceuticals Limited does not include Scope 3 emissions for the reported periods, with noted missing data points for purchased goods and services, business travel, and employee commute.

GlaxoSmithKline Pharmaceuticals Limited's climate commitments and emissions data are cascaded from its ultimate parent, GSK plc, as indicated by its status as a current subsidiary. While specific reduction targets for GlaxoSmithKline Pharmaceuticals Limited are not detailed in the provided information, GSK plc is involved in initiatives such as the Science Based Targets initiative (SBTi), CDP, RE100, and the Climate Pledge. These programmes typically involve setting ambitious greenhouse gas reduction targets across all scopes of emissions to align with climate science.